Arthritis

The European Commission ( EC ) has approved Rinvoq ( Upadacitinib, 15 mg ), an oral, once daily selective and...


The FDA ( U.S. Food and Drug Administration ) is alerting the public that preliminary results from a safety clinical...


The co-primary endpoint results from a recently completed post-marketing required safety study, ORAL Surveillance were presented. The primary objective of...


The objective of the study was to report efficacy and safety of Upadacitinib ( Rinvoq ) through 1 year in...


Pain is a core domain of psoriatic arthritis ( PsA ). A post hoc analysis has evaluated time to pain...


Rheumatoid arthritis ( RA ), along with glucocorticoid use, is associated with cardiovascular disease. Cardiovascular safety of glucocorticoids in rheumatoid...


An update of the European League Against Rheumatism ( EULAR ) rheumatoid arthritis management recommendations to account for the most...


The European Commission ( EC ) has granted marketing authorization for Jyseleca ( Filgotinib 200 mg and 100 mg tablets...



The U.S. Food and Drug Administration ( FDA ) has issued an emergency use authorization ( EUA ) for the...


Patients with autoimmune disease and lung cancer pose a multidisciplinary treatment challenge, particularly with the advent of immunotherapy. However, the...


In December 2019, a novel pneumonia caused by a previously unknown pathogen emerged in Wuhan, a city of 11 million...


The coronavirus disease 2019 ( COVID-19 ) virus, emerged in December 2019, has spread rapidly, with cases now confirmed in...


In phase 3 trials, Upadacitinib ( Rinvoq ), an oral JAK1-selective inhibitor, has been assessed as monotherapy versus Methotrexate (...


The FDA ( US Food and Drug Administration ) has approved Cosentyx ( Secukinumab ) for the treatment of active...


The SELECT‐EARLY trial studied the effect of Upadacitinib ( Rinvoq ), an oral, reversible, JAK inhibitor, as monotherapy in patients...


Upadacitinib ( Rinvoq ) was developed as a JAK1-selective inhibitor by exploiting differences in the non-conserved domains outside the active...


Filgotinib is JAK-1 selective catalytic inhibitor. Due to its target selectivity, Filgotinib is estimated to have a good efficacy and...


Objective of the study was to disentangle the role of nonsteroidal anti-inflammatory drugs ( NSAIDs ) in the increased risk...


The FDA ( U.S. Food and Drug Administration ) has approved Rinvoq ( Upadacitinib ), a 15 mg, once-daily oral...